Dec-16 -

Melanoma Group

EORTC 16032 – Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.

Some Melanoma metastasis contain the MAGE-A3 antigen which can be targeted by special antitumor immune cells. This EORTC study compared two treatments in patients with metastatic melanoma expressing MAGE-A3, and found that immunization against MAGE-A3 improved overall survival. The EORTC Melanoma Group also reported that the females have longer time to reoccurrence and improved overall survival than males in stage II-IV melanoma patients.


Go to Top